image
Healthcare - Medical - Devices - NYSE - US
$ 5.84
0 %
$ 224 M
Market Cap
-1.91
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVRO stock under the worst case scenario is HIDDEN Compared to the current market price of 5.84 USD, Nevro Corp. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVRO stock under the base case scenario is HIDDEN Compared to the current market price of 5.84 USD, Nevro Corp. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVRO stock under the best case scenario is HIDDEN Compared to the current market price of 5.84 USD, Nevro Corp. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVRO

image
$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 Mar
FINANCIALS
409 M REVENUE
-3.92%
-126 M OPERATING INCOME
-27.11%
-113 M NET INCOME
-23.02%
-19.4 M OPERATING CASH FLOW
66.96%
14.6 M INVESTING CASH FLOW
303.04%
-4.2 M FINANCING CASH FLOW
-8.49%
106 M REVENUE
8.91%
-51.4 M OPERATING INCOME
-270.75%
-53.1 M NET INCOME
-246.14%
18.6 M OPERATING CASH FLOW
580.64%
5.27 M INVESTING CASH FLOW
181.86%
632 K FINANCING CASH FLOW
278.53%
Balance Sheet Nevro Corp.
image
Current Assets 476 M
Cash & Short-Term Investments 293 M
Receivables 71.9 M
Other Current Assets 112 M
Non-Current Assets 77.8 M
Long-Term Investments 0
PP&E 47.7 M
Other Non-Current Assets 30.1 M
52.82 %12.98 %20.15 %8.62 %5.43 %Total Assets$553.8m
Current Liabilities 103 M
Accounts Payable 24.5 M
Short-Term Debt 38 M
Other Current Liabilities 40.5 M
Non-Current Liabilities 220 M
Long-Term Debt 213 M
Other Non-Current Liabilities 6.7 M
7.58 %11.76 %12.55 %66.04 %Total Liabilities$322.8m
EFFICIENCY
Earnings Waterfall Nevro Corp.
image
Revenue 409 M
Cost Of Revenue 139 M
Gross Profit 270 M
Operating Expenses 396 M
Operating Income -126 M
Other Expenses -12.8 M
Net Income -113 M
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)409m(139m)270m(396m)(126m)13m(113m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
65.98% GROSS MARGIN
65.98%
-30.90% OPERATING MARGIN
-30.90%
-27.77% NET MARGIN
-27.77%
-49.11% ROE
-49.11%
-20.48% ROA
-20.48%
-26.07% ROIC
-26.07%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Nevro Corp.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -113 M
Depreciation & Amortization 14.1 M
Capital Expenditures -9.79 M
Stock-Based Compensation 51.2 M
Change in Working Capital 14.6 M
Others 8.36 M
Free Cash Flow -29.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Nevro Corp.
image
Wall Street analysts predict an average 1-year price target for NVRO of $6.11 , with forecasts ranging from a low of $4 to a high of $8 .
NVRO Lowest Price Target Wall Street Target
4 USD -31.51%
NVRO Average Price Target Wall Street Target
6.11 USD 4.64%
NVRO Highest Price Target Wall Street Target
8 USD 36.99%
Price
Max Price Target
Min Price Target
Average Price Target
131312121111101099887766554433May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Nevro Corp.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Nevro Corp. Investigated by Federman & Sherwood for Data Breach OKLAHOMA CITY, April 03, 2025 (GLOBE NEWSWIRE) -- Nevro Corp. investigated by Federman & Sherwood for data breach. On April 3, 2025, Nevro Corp. filed notice of a data breach with the Attorney General of Texas. globenewswire.com - 2 weeks ago
Why Is Nevro (NVRO) Up 0.9% Since Last Earnings Report? Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? zacks.com - 2 weeks ago
Globus Medical completes acquisition of Nevro Corp. AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. globenewswire.com - 2 weeks ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w. businesswire.com - 4 weeks ago
Here's Why you Should Retain Nevro Stock in Your Portfolio Now NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market. zacks.com - 1 month ago
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level. zacks.com - 1 month ago
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. zacks.com - 1 month ago
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results REDWOOD CITY, Calif. , March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. prnewswire.com - 1 month ago
Shareholder Alert: The Ademi Firm investigates whether Nevro Corp. is obtaining a Fair Price for its Public Shareholders MILWAUKEE , Feb. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. prnewswire.com - 1 month ago
Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy? Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain? GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities. zacks.com - 2 months ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the. businesswire.com - 2 months ago
8. Profile Summary

Nevro Corp. NVRO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 224 M
Dividend Yield 0.00%
Description Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Contact 1800 Bridge Parkway, Redwood City, CA, 94065 https://www.nevro.com
IPO Date Nov. 6, 2014
Employees 1099
Officers Mr. Roderick H. MacLeod Senior Vice President & Chief Financial Officer Ms. Shana D. Ross M.B.A. Senior Vice President & Chief Human Resources Officer Dr. David Caraway M.D., Ph.D. Senior Vice President & Chief Medical Officer Mr. Kashif Rashid J.D. Senior Vice President of Corporate Development & Chief Legal Officer Mr. Kevin R. Thornal President, Chief Executive Officer & Director Mr. Peter A. Socarras Vice President, General Counsel & Corporate Secretary Ms. Angeline C. McCabe Vice President of Investor Relations & Corporate Communications Mr. Greg Siller Senior Vice President & Chief Commercial Officer Mr. Christofer Christoforou Senior Vice President & Chief Operating Officer